-

EvoEndo Announces Ambulatory Payment Classification (APC) Reassignments for Flexible Transnasal Esophagogastroduodenoscopy (EGD)

DENVER--(BUSINESS WIRE)--EvoEndo®, Inc. (“EvoEndo”), a medical device company developing systems for Unsedated Transnasal Endoscopy (TNE), is pleased to share recent decisions announced by the Centers for Medicare and Medicaid Services (CMS) in its CY 2023 Hospital Outpatient Prospective Payment System (OPPS) final rule. Based on information submitted to CMS including the cost of the EvoEndo Model LE Single-Use Gastroscope and its recent 510(k) FDA clearance, CMS decided to modify the APC assignments for CPT codes 0652T, 0653T and 0654T. Effective July 1, 2023, the APC assignment for CPT 0652T (transnasal diagnostic EGD) and 0653T (transnasal EGD with biopsy) will change from APC 5301 (Level 1 Upper GI Procedures) to APC 5302 (Level 2 Upper GI Procedures). Additionally, CPT 0654T (transnasal EGD with insertion of intraluminal tube or catheter) will be moved from APC 5302 (Level 2 Upper GI Procedures) to APC 5303 (Level 3 Upper GI Procedures).1

“We thank CMS for its consideration. We look forward to sharing this new payment alignment with healthcare providers as they consider the clinical and financial value of unsedated transnasal endoscopy,” said Heather Underwood, Chief Executive Officer at EvoEndo.

“Unsedated transnasal endoscopy with the EvoEndo® Single-Use Endoscopy System is designed to reduce preparation and recovery time for upper endoscopy procedures and to eliminate potential risks associated with sedation. This is especially important for our pediatric patients in need of diagnostic endoscopy with Eosinophilic Gastrointestinal Disorders,” remarks Dr. Ali Mencin, Chief of Pediatric Gastroenterology, Hepatology, and Nutrition at Columbia University Medical Center.

The EvoEndo® Single-Use Endoscopy System received FDA 510(k) clearance in February 2022. The EvoEndo System includes a sterile, single-use, flexible gastroscope designed for unsedated transnasal upper endoscopy, and a small portable video controller. The EvoEndo Comfort Kit includes virtual reality (VR) goggles for patient distraction during the unsedated transnasal endoscopy procedure. Unsedated TNE can be used to evaluate and diagnose a wide range of upper GI conditions that may require frequent monitoring, including eosinophilic esophagitis (EoE), dysphagia, celiac disease, gastroesophageal reflux disease, Barrett’s esophagus, malabsorption, and abdominal pain. The EvoEndo System is only intended for use by medical professionals. Physicians and other medical providers interested in learning more about EvoEndo’s TNE system or to schedule demonstrations and training can contact the company here.

About EvoEndo®

EvoEndo®, Inc. is a medical device company developing sterile single-use, flexible endoscopes that enable unsedated endoscopic procedures. EvoEndo’s technology allows pediatric patients and adults alike to consider an unsedated option for routine endoscopies in a clinic setting without the use of general anesthesia or sedation. To learn more, please visit: https://evoendo.com/.

____________________________
1
As is always the case, providers should independently verify the procedure and product codes.

Contacts

EvoEndo®, Inc.
Annie Harmon
Director of Marketing & Communications
annie@evoendo.com
(720) 580-3555

Lazar FINN Partners
Erich Sandoval, Lazar FINN
Erich.sandoval@finnpartners.com
(917) 497-2867

EvoEndo, Inc.

Details
Employees: undefined

Release Versions

Contacts

EvoEndo®, Inc.
Annie Harmon
Director of Marketing & Communications
annie@evoendo.com
(720) 580-3555

Lazar FINN Partners
Erich Sandoval, Lazar FINN
Erich.sandoval@finnpartners.com
(917) 497-2867

More News From EvoEndo, Inc.

Children’s Hospital Los Angeles is the First in California to Use the EvoEndo® System for Unsedated Pediatric Endoscopy

DENVER--(BUSINESS WIRE)--EvoEndo®, Inc. (“EvoEndo”), a medical device company developing systems for unsedated Transnasal Endoscopy (TNE), is pleased to announce that Children’s Hospital Los Angeles (CHLA) is the first care center in California to use the EvoEndo® Single-Use Endoscopy System to perform a diagnostic unsedated TNE of the Upper Gastrointestinal (GI) Tract. CHLA is the largest provider of care for children in Los Angeles County and, according to U.S. News & World Report’s 2022-...

EvoEndo® Announces Key Leadership Transitions

DENVER--(BUSINESS WIRE)--EvoEndo®, Inc. (“EvoEndo” or the “Company”), a medical device company developing platforms for Unsedated Transnasal Endoscopy (TNE), today announced key leadership changes. Effective April 4, 2023, Jonathan T. Hartmann will become President and Chief Executive Officer, and Ryan Hartman (no relation) will become Chief Operating Officer. The previous CEO, Dr. Heather Underwood, PhD, will stay with the company through April to support the transition. Mr. Jonathan T. Hartma...

EvoEndo Poised to Transform Clinical Endoscopy Practice With The EvoEndo® Single-Use Unsedated Transnasal Endoscopy (TNE) System

DENVER--(BUSINESS WIRE)--EvoEndo®, Inc. (“EvoEndo”), a medical device company which developed a single use system that allows for unsedated Transnasal Endoscopy (TNE), has announced the completion of an $8.4 million Series A financing round led by founding investor TLP Investment Partners LLC (TLP) and including the Sunshine Charitable Foundation and the Jill and Paul Meister family. Proceeds from the financing will be used to support the initial commercial launch of the EvoEndo® Single-Use End...
Back to Newsroom